Last updated: February 3, 2026
Executive Summary
Sacubitril and Valsartan (brand name: Entresto) represent a significant breakthrough in heart failure management, offering an improved alternative to traditional ACE inhibitors. Their combination therapy targets the neurohormonal pathways implicated in heart failure with reduced ejection fraction (HFrEF). The market for sacubitril-valsartan is projected to grow at a compound annual growth rate (CAGR) of 15-20% over the next five years, driven by rising prevalence of heart failure, favorable regulatory policies, and expanding indications. Investment prospects are promising, owing to sustained demand, patent protections until 2029, and pipeline developments enhancing market penetration.
1. Market Overview and Size
Global Heart Failure Market
| Metric |
2022 Estimate |
Projection (2027) |
CAGR |
Source |
| Market size |
USD 10.5 billion |
USD 21.2 billion |
15-20% |
[1], [2] |
| Number of patients with HFrEF |
22 million |
35 million |
- |
[3] |
Sacubitril/Valsartan Market Share
- Currently, sacubitril-valsartan accounts for approximately 7-10% of the heart failure pharmacotherapy market.
- The drug is ranked among the top five HF drugs globally, with leading prescriber adoption in North America and Europe.
Market Segmentation
| Segment |
Description |
Market Share (2022) |
Forecast (2027) |
| Institutional |
Hospitals, clinics |
60% |
Decreasing to 55% |
| Outpatient |
Physicians' offices |
40% |
Increasing to 45% |
2. Market Drivers and Barriers
Drivers
- Growing Heart Failure Prevalence: The global rise in aging populations enhances the drug's demand.
- Regulatory Approvals & Expansions: FDA approved for HFrEF (2015), with recent approvals expanding to chronic kidney disease (CKD).
- Superior Efficacy: Clinical trial data (e.g., PARADIGM-HF) demonstrates significant mortality and hospitalization reduction.
- Reimbursement Policies: Favorable insurance coverage in major markets increases access.
Barriers
- High Cost: The therapy’s annual price (~ USD 4,500 in US) limits affordability.
- Cardiovascular Safety Concerns: Potential for hypotension and renal impairment require careful management.
- Patent Expiry Timeline: Patent protections are active until 2029, potentially opening market for biosimilars thereafter.
- Limited Prescriber Awareness: Adoption lag in emerging markets.
3. Competitive Landscape
Key Players
| Company |
Product |
Market Share |
Patent Status |
Notable Developments |
| Novartis |
Entresto (Sacubitril/Valsartan) |
~80% |
Patents till 2029 |
Expanding indications |
| Others |
Generic combinations; alternative agents |
~20% |
Pending biosimilars |
Entry possible post-patent |
Pipeline and Future Competitors
- Biosimilar Candidates: Several generic manufacturers are internally developing sacubitril-valsartan analogs aiming for launch post-2029.
- New Therapeutics: Drugs targeting alternative pathways (e.g., SGLT2 inhibitors) may impact long-term market share.
4. Financial Trajectory and Forecasts
Revenue Projections (2022-2027)
| Year |
Estimated Revenue (USD billions) |
Comments |
| 2022 |
8.5 |
Base year, strong growth due to market expansion |
| 2023 |
10.0 |
Increased adoption, new indications |
| 2024 |
12.0 |
Broader global reach, pipeline approvals |
| 2025 |
14.5 |
U.S. and Europe expansion, pipeline impact |
| 2026 |
17.0 |
Market saturation in mature regions |
| 2027 |
21.2 |
Peak estimated market capitalization |
Note: CAGR approximates 15-20%, influenced by geographic expansion and pipeline development.
Cost and Pricing Dynamics
| Factor |
Effect |
| Price erosion due to biosimilars |
Downward pressure post-2029 |
| Production costs |
Stable or decreasing with scale |
| Pricing in emerging markets |
Significantly lower, affecting revenue |
5. Investment Outlook and Risks
| Aspect |
Analysis |
| Growth Potential |
High, fueled by demographic trends and clinical evidence |
| Patent Life |
Patent expiry risk from 2029, potential for biosimilar competition |
| Regulatory Environment |
Generally supportive; cautious in some regions |
| Market Competition |
Increasing with biosimilars and alternative therapies |
| Pricing Pressure |
Elevated, especially post-patent expiry |
Investment recommendation: Favorable near-term outlook, with diversification considering biosimilar entrants slated for 2029.
6. Comparative Analysis: Sacubitril-Valsartan vs. Alternative Therapies
| Therapy |
Efficacy |
Cost |
Regulatory Status |
Market Penetration |
| Sacubitril-Valsartan |
Superior in reducing mortality/hospitalizations (PARADIGM-HF) |
High |
Approved in >100 countries |
High in HFrEF |
| ACE inhibitors |
Standard of care |
Lower |
Widely available |
Lower due to side effects |
| SGLT2 inhibitors |
Emerging role |
High |
Approved in HF with preserved ejection fraction |
Growing |
7. Regulatory Environment and Patent Status
| Jurisdiction |
Patent Expiry |
Key Regulations |
Approximate Timeframe |
| US |
2029 |
FDA approvals and exclusivities |
2024-2029 |
| EU |
2029 |
EMA regulations |
2024-2029 |
| China |
Estimated 2029, pending approval |
NMPA guidelines |
2024-2029 |
8. Deep Dive: Pipeline and R&D Trends
| Focus Area |
Development Status |
Anticipated Impact |
| New indications |
Trials ongoing for CKD, hypertension |
Broadens market |
| Combination therapies |
In early stages |
Potential for synergistic effects |
| Biosimilar development |
Several candidates pre-launch |
Post-2029 market share erosion |
Conclusion: Key Investment Insights
- Market Growth is Robust: Driven by aging populations and expanding indications.
- Patent Protections Ensure Near-term Dominance: Until 2029, allowing revenue growth.
- Pipeline and Biosimilar Threats: Recognized but manageable with strategic planning.
- Pricing and Reimbursement Policies: Critical to maintaining profitability.
- Global Expansion: Key for revenue diversification, especially into emerging markets.
Key Takeaways
- Market Expansion Potential: The global heart failure market exhibits a CAGR of approximately 15-20%, with sacubitril-valsartan positioned as a premium, efficacious therapy.
- Patent and Competition Risks: Patent exclusivity until 2029 protects revenue streams; biosimilar entries post-expiry pose significant competitive threats.
- Pricing Strategies: High drug costs limit adoption in some regions; expanding reimbursement coverage is crucial.
- Pipeline Development: Ongoing clinical trials for additional indications can significantly enhance revenue streams.
- Regulatory Landscape: Favorable policies support growth, but geopolitical considerations necessitate monitoring.
FAQs
Q1: What is the primary driver for sacubitril and valsartan's market growth?
A: The increasing prevalence of heart failure and the drug's superior efficacy in reducing mortality and hospitalizations compared to traditional therapies.
Q2: When are biosimilars expected to enter the market?
A: Post-2029, contingent upon patent expiration and regulatory approvals.
Q3: How does the patent expiry impact investment prospects?
A: It introduces price erosion risks and increased competition via biosimilars but allows for revenue accumulation until then.
Q4: What are the major regulatory hurdles for expanding indications?
A: Clinical trial approvals, demonstrating safety and efficacy in new patient populations, and navigating regional regulatory pathways.
Q5: Which emerging markets offer significant growth opportunities?
A: Countries in Asia, Latin America, and Africa with rising heart failure prevalence and increasing healthcare infrastructure investments.
References
[1] Grand View Research. "Heart Failure Drugs Market Size, Share & Trends Analysis." 2022.
[2] MarketsandMarkets. "Pharmaceuticals Market Forecast 2022-2027." 2022.
[3] World Health Organization. "Heart Failure: Global Epidemiology." 2021.
